Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Inclusion Criteria

• •Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
• •* Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
• •OR
• •Subjects who have or have had a solid tumor diagnosis and any of the following:
• •* At least 4 months of exposure to a PARP inhibitor
• •* Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm